Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 janv. 2020 08h00 HE | Source: Aravive, Inc.

Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

HOUSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
09 janv. 2020 16h05 HE | Source: Aravive, Inc.

Aravive Announces Management Changes

Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline Jay Shepard to Assume Role of Chairman of the Board of...
20 déc. 2019 08h00 HE | Source: Aravive, Inc.

Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis

HOUSTON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a...
02 déc. 2019 08h00 HE | Source: Aravive, Inc.

Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference

HOUSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
27 nov. 2019 08h30 HE | Source: Aravive, Inc.

Aravive Announces Pricing of Public Offering of Common Stock

HOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of...
26 nov. 2019 17h14 HE | Source: Aravive, Inc.

Aravive Announces Proposed Public Offering of Common Stock

HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of...
20 nov. 2019 07h00 HE | Source: Aravive, Inc.

Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer

Statistically significant four-fold increase in progression free survival observed in women with high AVB-500 levels Aravive to Host Conference Call Today at 8 a.m. EST HOUSTON, Nov. 20, 2019 ...
12 nov. 2019 08h00 HE | Source: Aravive, Inc.

Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer

HOUSTON and WILMINGTON, Del., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of...
08 nov. 2019 13h11 HE | Source: Aravive, Inc.

CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates

HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, November 7th by Aravive, Inc. (Nasdaq: ARAV), please note that in the last sentence of the second...
07 nov. 2019 16h05 HE | Source: Aravive, Inc.

Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates

HOUSTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...

Page précédente